Your browser doesn't support javascript.
loading
Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit, Alina; Zaidman, Daniel; Kalid, Ori; Bloch, Itai; Doron, Dvir; Yarnizky, Tali; Buch, Idit; Segev, Idan; Ben-Zeev, Efrat; Segev, Elad; Kobiler, Oren.
Afiliación
  • Shitrit A; The Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, 69978, Tel Aviv, Israel.
  • Zaidman D; Department of Organic Chemistry, Weizmann Institute of Science, Rehovot, Israel.
  • Kalid O; , Pardes Hana, Israel.
  • Bloch I; Biotechnology Department, Migal - Galilee Research Institute, Kiryat-Shmona, Israel.
  • Doron D; Chemical & Computational Toxicology, Non-Clinical Development, Global R&D, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
  • Yarnizky T; Tali Yarnizky Scientific Consulting, Maccabim-Reut, Israel.
  • Buch I; Emendo Biotherapeutics Ltd., Ness Ziona, Israel.
  • Segev I; , Rishon-LeZion, Israel.
  • Ben-Zeev E; The Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
  • Segev E; Department of Applied Mathematics, Faculty of Science, Holon Institute of Technology, Holon, Israel.
  • Kobiler O; The Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, 69978, Tel Aviv, Israel. okobiler@tauex.tau.ac.il.
Sci Rep ; 10(1): 20808, 2020 11 30.
Article en En | MEDLINE | ID: mdl-33257760
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antivirales / Inhibidores de Proteasas / Evaluación Preclínica de Medicamentos / Proteasas 3C de Coronavirus / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Prognostic_studies Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antivirales / Inhibidores de Proteasas / Evaluación Preclínica de Medicamentos / Proteasas 3C de Coronavirus / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Prognostic_studies Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article